
Consensus conference on salivary gland tumors

Adenoid-cystic carcinoma and high-grade neoplasms

A common commitment towards the future





October 23rd-24th 2014, School of Medicine, University of Brescia (Italy)











Consensus conference on salivary gland tumors

Adenoid-cystic carcinoma and high-grade neoplasms

Dear Colleagues,

consensus.

The challenging management of salivary gland malignancies asks for a multidisciplinary approach. In the last few years the knowledge in the field of basic science has grown rapidly, and is probably becoming the driver for therapeutic choices in the future. In keeping with this concept, the present conference wants to gather experts in the fields of Pathology, Imaging, Surgery (ENT and Maxillo-Facial Surgeons), Radiation and Medical Oncology to prepare for the future. Together we will delineate by consensus the management of "problematic" salivary gland tumors for the next years.

This will be a 2-day consensus conference, with the first day dedicated to adenoid-cystic carcinoma, and the second day focused on high-grade salivary gland malignancies. Three topics for discussion (diagnosis, therapeutic approach to the primary lesion, treatment of recurrent/metastatic disease) will characterize each day of the meeting. Each session will consist of two parts: in the first, the "state of the art" will be defined by experts, whereas in the second part the panelists and audience will try to reach a

For each topic (diagnosis, treatment of primary tumor and metastatic disease), a chairman and experts will be identified. They will be in charged of writing a document that will be submitted to the panelists for comments, at least 6 months before the date of the meeting. The final document will be discussed during the meeting between experts and the audience to reach a consensus.

The meeting will be held under the auspices of















Congress Directors

Adel El-Naggar, Department of Pathology, M.D. Anderson Cancer Center, Houston, USA **Ehab Hanna**, Department of Head and Neck Surgery, M.D. Anderson Cancer Center, Houston, USA

Lisa Licitra, Head and Neck Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Roberto Maroldi, Department of Radiology, University of Brescia, Italy Piero Nicolai, Department of Otorhinolaryngology, University of Brescia, Italy

Scientific Secretariat

Laura Locati, Head and Neck Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Davide Lombardi, Department of Otorhinolaryngology, University of Brescia, Italy **Ester Orlandi**, Department of Radiation Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

William Vermi, Department of Pathology, University of Brescia, Italy

Faculty

International Faculty

Ian Casselman, Department of Radiology, A.Z. St.-Jan Hospital, Bruges, Belgium Alexandra Jensen, Department of Radiation Oncology, University of Heidelberg, Germany Isabel Fonseca, Serviço de Anatomia Patológica, Instituto Português de Oncologia Francisco Gentil, Lisboa & Instituto de Anatomia Patológica, Faculdade de Medicina de Lisboa, Portugal

Nicole J.M. Freling, Radiology Department, Academic Medical Centre, Amsterdam, The Netherlands

David G. Pfister, Head and Neck Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, USA

Goran Stenman, Department of Pathology, Sahlgrenska Cancer Center, University of Göteborg, Sweden

Carla M. van Herpen, Department of Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

Vincent Vander Poorten, Department of Head Neck Surgery, University of Leuven, Belgium

Philippe Vielh, Department of Pathology, Institut Gustave Roussy, Paris, France **Randal Weber**, Department of Head Neck Surgery, Houston, USA

Faculty

Italian Faculty

Mario Airoldi, Department of Medical Oncology, University of Turin
Antonino R. Antonelli, Department of Otorhinolaryngology, University of Brescia
Alfredo Berruti, Department of Medical Oncology, University of Brescia
Francesco Bertagna, Department of Nuclear Medicine, University of Brescia
Bernardo Bianchi, Department of Maxillofacial Surgery, University of Parma
Mario Bussi, Department of Otorhinolaryngology, University "S.Raffaele", Milan
Flavio Crippa, Nuclear Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
Fabio Facchetti, Department of Pathology, University of Brescia

Carlo Fallai, Department of Radiation Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

Davide Farina, Department of Radiology, University of Brescia

Piero Fossati, Department of Radiation Oncology, National Center for Adrotherapy "CNAO", Milan

Raffaele Giubbini, Department of Nuclear Medicine, University of Brescia

Gioacchino Giugliano, Department of Head and Neck Surgery, Istituto Europeo di Oncologia, Milan

Marco Guzzo, Head and Neck Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan Stefano Magrini, Department of Radiation Oncology, University of Brescia

Ugo Pastorino, Thoracic Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan **Cesare Piazza**, Department of Otorhinolaryngology, University of Brescia

Giuseppe Sanguineti, Department of Radiation Oncology, National Cancer Institute "Regina Elena", Rome

Enrico Sesenna, Department of Maxillofacial Surgery, University of Parma Giuseppe Spriano, Department of Head and Neck Surgery, National Cancer Institute "Regina Elena", Rome

Session Presidents

Marco Benazzo, Pavia Fausto Chiesa, Milano Marco De Vincentiis, Roma Gaetano Paludetti, Roma Francesco Pia, Novara Giovanni Succo, Torino

Program

07.15-07.55	Registration and welcome corree
08.00-08.15	Welcome and Introduction
08.15-08.30	Honorary lecture: The history of adenoid-cystic carcinoma
	A. R. Antonelli

Day 1, October 23rd 2014: Adenoid-cystic carcinoma (ACC)

08.30-08.50 Lecture in tribute to Marina Speck:

Overview on molecular features of ACC and their impact on treatment. (A. El-Naggar) (20')

08.50-10.00 1st Session: DIAGNOSIS

President: F. Chiesa Chairman: A. El-Naggar

Panelists: I. Casselman, F. Crippa, F. Facchetti

- MYB and MYB-NFIB as diagnostic and therapeutic targets in ACC (G. Stenman) (15')
- FNAB and histology: the most frequent missclassifications (I. Fonseca) (10')
- Overview on perineural spread: cellular and molecular mechanisms (W. Vermi) (10')
- The role and limits of imaging (CT, MRI, and PET) in treatment planning (R. Maroldi-R. Giubbini) (25')

10.00-11.10 Consensus on:

- Histopathologic diagnostic criteria
- Diagnostic imaging

11.10-11.30 Coffee break

Day 1, October 23rd 2014

11.30-13.10 2nd Session: TREATMENT OF THE PRIMARY LESION

President: G. Paludetti
Chairman: V. Vander Poorten

Panelists: P. Fossati, G. Giugliano, S. Magrini, L. Licitra, D. Lombardi

- Indications, suggestions and problems in surgical treatment of major salivary glands adenoid-cystic carcinoma (E. Hanna) (15')
- Indications, suggestions and problems in surgical treatment of minor salivary glands adenoid-cystic carcinoma (P. Nicolai) (15')
- Reconstructive issues and facial reanimation (C. Piazza, E. Sesenna, B. Bianchi) (20')
- Indications to RT in an adjuvant and exclusive setting (+/- CHT) (E. Orlandi) (20')
- Carbon-ion therapy (A. Jensen) (20')

13.10-14.10 Lunch

14.10-15.25 Consensus on:

- Treatment of the primary lesion
- Reconstruction and facial reinnervation
- Adjuvant and curative RT +/- CHT

15.25-16.40 3rd Session: FOLLOW-UP AND RECURRENT/METASTATIC DISEASE

President: G. Succo Chairman: R. Weber

Panelists: E. Hanna, E. Orlandi, M. Airoldi, NJ.M. Freling, F. Bertagna

- The role of imaging (CT, MRI and PET) in the post-treatment surveillance (I. Casselman) (15')
- The role of surgery in the treatment of local relapse (V. Vander Poorten) (15')
- The role of reirradiation in the treatment of local relapse (C. Fallai) (15')
- The role of surgery in the treatment of lung metastasis (U. Pastorino) (10')
- Therapy for locally advanced, recurrent and metastatic disease (D. G. Pfister) (20')

16.40-17.00 Coffee break

17.00-18.30 Consensus on:

- Follow-up strategy
- Indications for surgery and/or reirradiation for recurrent primary lesions
- Indications for surgery for lung metastases
- Medical treatment for metastatic disease

Day 2, October 24th 2014:

High-grade salivary gland tumors (High-grade MEC, Salivary duct carcinoma, Carcinoma ex-pleomorphic adenoma, Adenocarcinoma)

08.00-08.15 Welcome coffee

08.15-08.35 Lecture Overview on molecular features of high-grade salivary gland tumors and their impact on treatment (A. El-Naggar) (20')

08.35-09.35 1st Session: DIAGNOSIS

President: M. Benazzo Chairman: F. Facchetti

Panelists: I. Casselman, R. Giubbini, A. El-Naggar

- Chromosomal rearrangements and fusion oncogenes (G. Stenman) (20')
- The role of FNA in diagnosis and molecular testing of salivary gland cancers (P. Vielh) (15')
- Histopathologic definition and differential diagnosis (I. Fonseca) (15')
- The role and limits imaging (CT, MRI and PET) in treatment planning (D. Farina F. Crippa) (20')

09.55-11.10 Consensus on:

- Histopathologic diagnostic criteria
- Diagnostic imaging

11.10-11.30 Coffee break

11.30-12.30 2nd Session: TREATMENT OF THE PRIMARY LESION AND THE NECK

President: M. De Vincentiis

Chairman: M. Bussi

Panelists: M. Guzzo, A. Jensen, A. Berruti, L. Locati

- Indications, suggestions, and problems in surgical treatment of high-grade salivary gland tumors (V. Vander Poorten) (15')
- Indications, suggestions, and problems in surgical treatment of the neck in high-grade salivary glands tumors (G. Spriano) (15')
- Indications for RT in an adjuvant and exclusive setting (+/- CHT) (G. Sanguineti) (20')

Day 2, October 24th 2014

12.30-13.30 Lunch

13.30-14.45 Consensus on:

- Surgical indications for the treatment of primary lesions and the neck
- Indications for adjuvant treatment and exclusive RT (+/-ChT)

14.45-16.00 3rd Session: FOLLOW-UP AND RECURRENT/METASTATIC DISEASE

President: F. Pia Chairman: L. Licitra

Panelists: E. Hanna, C. Fallai, R. Maroldi/D. Farina, F. Bertagna

- The role of imaging in the post-treatment surveillance (NJ.M. Freling F. Crippa) (15')
- The role of surgery in the treatment of loco-regional relapse (R. Weber) (15')
- The role of reirradiation in the treatment of loco-regional relapse (S. Magrini) (15')
- Systemic therapy for locally advanced, recurrent and metastatic disease (C. M. Van Herpen) (15')

16.00-16.15 Coffee break

16.15 -17.30 Consensus on:

- Follow-up strategy
- Indications to surgery and/or re-irradiation for recurrent primary lesions
- Systemic treatment for metastatic disease

17.30-18.00 Closing remarks

General informations

Language The official language is English.

Course Venue Aula Magna School of Medicine - University of Brescia

Via Valsabbina, 19 - 25121 Brescia - Italy

ECM/CME

The Consensus Conference has been granted for ECM/CME accreditation by:

Italian Ministry of Health (ECM) For Italian Medical Doctors: Oncology, Radiotherapy, Maxillo-Facial Surgery, Otorhinolaryngology, Anatomical Pathology, Radiodiagnostics - 18 ECM points

12 European CME credits (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME)

European Accreditation

European Accreditation is granted by the EACCME in order to allow participants who attend the above-mentioned activity to validate their credits in their own country.

The 'Consensus conference on salivary gland tumors Adenoid-cystic carcinoma and high-grade neoplasms A common commitment towards the future' is designated for a maximum of (or 'for up to') 12 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

EACCME credits

Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. The EACCME credit system is based on 1 ECMEC per hour with a maximum of 3 ECMECs for half a day and 6 ECMECs for a full-day event.

How to reach the University of Brescia-School of Medicine

By car Highway A4 Milano-Venezia.

- Exit Brescia Ovest; at the exit follow Tangenziale Ovest proceed along Tangenziale Nord. Follow for Stadio or Ospedale, proceed along via Oberdan. Go through, turn left for Via Triumplina and after 800 mt. turn right through Via Branze, on your left there's the School of Engineering and on the right hand there is School of Medicine.
- Exit Brescia Centro; at the exit take the Tangenziale Sud follow the road signs that take to Tangenziale. Please follow the one with Val Trompia, Milano or Bergamo. Arrived in the Tangenziale, proceed along till the road sign Tangenziale Ovest or Val Trompia. Now drive thorugh Tangenziale Ovest and go ahead to Tangenziale Nord, follow the road signs Stadio or Ospedale. Keep driving on via Oberdan till the end, then turn left on Via Triumplina and after 800 mt. turn right through Via Branze, on your left there's the School of Engineering and on the right hand there is School of Medicine.

By Train You can reach the School of Medicine via bus, subway or taxi

By Taxi The taxi stand is just outside the train station.

By Bus • Line 1: direction Mompiano, bus stop via Schivardi.

• Line 15: direction Villaggio Montini, bus stop Viale Europa, corner via Branze.

By Tube Blue line, stop at Europa

Parking Closed to the School of Medicine there are:

Parcheggio Ospedale Nord and Parcheggio Ospedale Sud.

Organizing Secretariat

Servizi C.E.C. Srl - Via Verdi, 18 - 24121 Bergamo - Italy Tel. +39.035.249899 Fax +39.035.237852 Mob. +39.339.6339391 k.qissi@servizicec.it www.servizicec.it

October 23rd-24th 2014, School of Medicine, University of Brescia (Italy)

Note	Note

October 23rd-24th 2014, School of Medicine, University of Brescia (Italy)

October 23rd-24th 2014, School of Medicine, University of Brescia (Italy)

Consensus conference on salivary gland tumors

Adenoid-cystic carcinoma and high-grade neoplasms

Organizing Secretariat

Servizi C.E.C. Srl Via Verdi, 18 - 24121 Bergamo - Italy Tel. +39.035.249899 Fax +39.035.237852 Mob. +39.339.6339391 k.gissi@servizicec.it www.servizicec.it